journal article·2022-11

Targeted co-delivery of a photosensitizer and an antisense oligonucleotide based on an activatable hyaluronic acid nanosystem with endogenous oxygen generation for enhanced photodynamic therapy of hypoxic tumors

Yanni Wu, Lei Ding, Cheng Zheng, Hongsheng Li, Ming Wu, Yupeng Sun, Xiaolong Liu, Xiaolong Zhang, Yongyi Zeng

Acta Biomaterialia· Volume 153
Publisher page

Abstract

Photodynamic therapy (PDT) is a promising cancer treatment modality with advantages of minimal invasiveness, repeatable therapy, and mild systemic toxicity. However, the limited bioavailability of photosensitizer (PS), tumor hypoxia, and the presence of antiapoptotic proteins in cancer cells, has hampered the efficiency of PDT. To address these limitations, herein, we developed a hyaluronic acid (HA) based nanosystem (HA-Ce6-Hemin@DNA-Protamine NPs, HCH@DP) loaded with chlorin e6 (Ce6, as PS), hemin (as mimetic catalase) and antisense oligonucleotide (ASO) of B-cell lymphoma 2 (Bcl-2) anti-apoptosis protein via a simple electrostatic self-assembly method for enhanced PDT of hypoxic solid tumors. The HCH@DP can target deliver the PS and ASO to tumor cells via cancer cell overexpressed HA receptors (i.e., CD44 or RHAMM). The Ce6 was released from HA-ss-Ce6 (HSC conjugates) after the reaction of cleavable disulfide bond with glutathione (GSH), which recovered the fluorescence and phototoxicity of Ce6 upon laser irradiation. Meanwhile, the catalase-mimicking hemin (degradation of HA-eda-hemin by hyaluronidase) decomposed the tumor overdressed endogenous H2O2 to oxygen, which relieved tumor hypoxia and further overcome hypoxia-associated resistance of PDT. Furthermore, the inhibition of Bcl-2 expression by Bcl-2 ASO also greatly improved the cellular sensitivity to PDT. Both in vitro and in vivo results showed the tumor cell targeting ability, hypoxia relief and significantly enhanced antitumor PDT efficacy of HCH@DP for hypoxic tumor cells upon laser irradiation. Thus, by improving the target delivery of PS and ASO, relieving tumor hypoxia, and down-regulation of anti-apoptotic proteins, this HCH@DP nanosystem achieved enhanced PDT efficiency against hypoxic tumors. In general, our work provided a promising strategy to increase the utilization of key components (PS and oxygen) of PDT and the cell sensitivity to PDT by targeting co-delivery PS and oligonucleotides to tumor cells via a biocompatible HA based carrier, thereby achieving efficiently PDT treatment of hypoxic solid tumors with potential translation possibility. STATEMENT OF SIGNIFICANCE: The efficiency of PDT against solid tumor is severely restricted by the limited bioavailability of photosensitizer, tumor hypoxia, and the presence of antiapoptotic proteins in cancer cells. Herein, we have developed an activatable hyaluronic acid (HA) based nanosystem (HA-Ce6-Hemin@DNA-Protamine NPs, HCH@DP) via a simple electrostatic self-assembly method for PDT treatment of hypoxic solid tumors. The HCH@DP enabled to target co-delivery of photosensitizer and antisense oligonucleotide to tumor cells, overcoming tumor hypoxia through in situ oxygen production and improving cellular sensitivity by efficiently reducing anti-apoptosis effect of cancer cells for synergistically enhancing PDT efficiency. This work suggests a promising strategy to develop small molecule drug and oligonucleotides co-delivery nanoplatforms for efficiently PDT treatment of hypoxic solid tumor.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (35)

Show source-provided references
1. Photodynamic therapy for cancer10.1038/nrc1071 ↗
2. Photodynamic therapy for prostate cancer-a review of current status and future promise10.1038/ncpuro1274 ↗
3. Photodynamic therapy of cancer: an update, CA10.3322/caac.20114 ↗
4. Clinical development of photodynamic agents and therapeutic applications10.1186/s40824-018-0140-z ↗
5. Clinical development and ppotential of photothermal and photodynamic therapies for cancer10.1038/s41571-020-0410-2 ↗
6. Photosensitizers for photodynamic therapy10.1002/adhm.201900132 ↗
7. Nanomaterials to relieve tumor hypoxia for enhanced photodynamic therapy10.1016/j.nantod.2020.100960 ↗
8. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy10.1038/nrm3722 ↗
9. The Bcl-2 protein family: arbiters of cell survival10.1126/science.281.5381.1322 ↗
10. Multishell nanoparticles with “linkage mechanism” for thermal responsive photodynamic and gas synergistic therapy10.1002/adhm.202002038 ↗
11. Photo-responsive hollow silica nanoparticles for light-triggered genetic and photodynamic synergistic therapy10.1016/j.actbio.2018.07.007 ↗
12. Ce6-modified carbon dots for multimodal-imaging-guided and single-NIR-laser-triggered photothermal/photodynamic synergistic cancer therapy by reduced irradiation power10.1021/acsami.8b19042 ↗
13. Photo-cross-linkable polymer dots with stable sensitizer loading and amplified singlet oxygen generation for photodynamic therapy10.1021/acsami.6b14325 ↗
14. Light-enhanced hypoxia-response of conjugated polymer nanocarrier for successive synergistic photodynamic and chemo-therapy10.1021/acsami.8b06491 ↗
15. An intelligent ZIF-8-gated polydopamine nanoplatform for in vivo cooperatively enhanced combination phototherapy10.1039/C9SC06337D ↗
16. Cancer cell-targeted photosensitizer and therapeutic protein co-delivery nanoplatform based on a metal-organic framework for enhanced synergistic photodynamic and protein therapy10.1021/acsami.0c09657 ↗
17. Chlorin e6 conjugated poly(dopamine) nanospheres as PDT/PTT dual-modal therapeutic agents for enhanced cancer therapy10.1021/acsami.5b01027 ↗
18. Activatable photosensitizers: agents for selective photodynamic therapy
19. Smart hyaluronidase-actived theranostic micelles for dual-modal imaging guided photodynamic therapy10.1016/j.biomaterials.2016.05.019 ↗
20. Strategies to improve photodynamic therapy efficacy by relieving the tumor hypoxia environment10.1038/s41427-021-00303-1 ↗
21. Conquering the hypoxia limitation for photodynamic therapy10.1002/adma.202103978 ↗
22. Hyperbaric oxygen therapy and cancer-a review10.1007/s11523-012-0233-x ↗
23. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy10.1038/ncomms9785 ↗
24. Hemoglobin-mediated biomimetic synthesis of paramagnetic O2-evolving theranostic nanoprobes for MR imaging-guided enhanced photodynamic therapy of tumor10.7150/thno.46228 ↗
25. Photocatalysis enhancement for programmable killing of hepatocellular carcinoma through self-compensation mechanisms based on black phosphorus quantum-dot-hybridized nanocatalysts10.1021/acsami.8b21820 ↗
26. Catalase-integrated hyaluronic acid as nanocarriers for enhanced photodynamic therapy in solid tumor10.1021/acsnano.9b01087 ↗
27. Modulation of hypoxia in solid tumor microenvironment with MnO2 nanoparticles to enhance photodynamic therapy10.1002/adfm.201600676 ↗
28. Platinum-carbon-integrated nanozymes for enhanced tumor photodynamic and photothermal therapy10.1039/D0NR02800B ↗
29. Oxygen-producing catalase-based prodrug nanoparticles overcoming resistance in hypoxia-mediated chemo-photodynamic therapy10.1016/j.actbio.2020.05.035 ↗
30. Hybrid nanospheres to overcome hypoxia and intrinsic oxidative resistance for enhanced photodynamic therapy10.1021/acsnano.9b09032 ↗
31. An inhibitor of Bcl-2 family proteins induces regression of solid tumours10.1038/nature03579 ↗
32. Light-induced self-escape of spherical nucleic acid from endo/lysosome for efficient non-cationic gene delivery10.1002/anie.202006890 ↗
33. Promotion of PDT efficacy by a Bcl-2 antagonist10.1111/j.1751-1097.2007.00267.x ↗
34. Perfluorocarbon-loaded and redox-activatable photosensitizing agent with oxygen supply for enhancement of fluorescence/photoacoustic imaging guided tumor photodynamic therapy10.1002/adfm.201806199 ↗
35. Intracellular delivery of antisense peptide nucleic acid by fluorescent mesoporous silica nanoparticles10.1021/bc5002714 ↗